DNA-damage repair inhibitors, such as PARP-inhibitors (PARPi), have the potential to enhance response to ICI through increased neo-antigen release, increased PD-L1 expression in the tumour microenvironment (TME) and increased immune-activating interferon signalling through upregulation of the cGAS-STING pathway [48]. The gene discussed is CD274; the disease is neoplasm.